Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Recipients of CJD-tainted blood and plasma derivatives should not be notified, AABB urges FDA cmte.

Executive Summary

RECIPIENTS SHOULD NOT BE NOTIFIED OF CJD-TAINTED BLOOD/PLASMA-DERIVATIVES, AABB urged in an open public hearing statement before FDA's Ad Hoc Advisory Committee on Creutzfeldt-Jakob Disease in Bethesda, Md. June 22. American Association of Blood Banks Transfusion Transmitted Disease Committee spokesperson Steven Kleinman, MD, said: "It would be exceptionally difficult to communicate this remote risk of infection and the symptoms of CJD along with the complete lack of intervention therapy without causing alarm in recipients."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026423

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel